User Fee Deal For Ad Review Funds Stems From PhRMA DTC Principles
This article was originally published in The Pink Sheet Daily
Executive Summary
The draft proposal is expected to be a stand-alone clause, not technically part of next year's reauthorization of the Prescription Drug User Fee Act.
You may also be interested in...
User Fees Would Fund Safety Oversight Throughout Product Life Cycles
PDUFA proposal expands scope of funding after FDA concludes that safety problems can occur well after a drug’s launch.
User Fees Would Fund Safety Oversight Throughout Product Life Cycles
PDUFA proposal expands scope of funding after FDA concludes that safety problems can occur well after a drug’s launch.
Pharma DTC Spend Increasing At Twice The Rate Of Physician Promotions, GAO Finds
A Government Accountability Office report, released Dec. 14, calls for improvements in FDA’s oversight of direct-to-consumer advertising.